Log in

Relevant bibliographies by topics / Dermatological Immunotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Dermatological Immunotherapy.

Journal articles on the topic 'Dermatological Immunotherapy'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Dermatological Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rigel, Darrell, and Brian Berman. "1. Introduction: Immunotherapy for Dermatological Conditions." Acta Dermato-Venereologica 83 (January 1, 2003): 5–7. http://dx.doi.org/10.1080/03658340310011870.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rigel B and B. Berman. "1. Introduction: Immunotherapy for Dermatological Conditions." Acta Dermato-Venereologica 83 (September 1, 2003): 5–7. http://dx.doi.org/10.1080/00015555-832142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zayad, Anas, Maira A. Bhatty, Maheen Ahmad, and Faiz Anwer. "Dermatological adverse events linked to talquetamab immunotherapy in multiple myeloma." BMJ Case Reports 17, no. 11 (2024): e260751. http://dx.doi.org/10.1136/bcr-2024-260751.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fane, Lauren S., Jimmy T. Efird, Charulata Jindal, and Tithi Biswas. "Dermatological Autoimmune Considerations of Immune Checkpoint Therapy." Biomedicines 10, no. 10 (2022): 2339. http://dx.doi.org/10.3390/biomedicines10102339.

Full text

Abstract:

The most common immune-related adverse events (irAEs) involve the skin, and several serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in melanoma. Patients with pre-existing skin autoimmune diseases (ADs) have been excluded from ICI studies for safety concerns, yet recent research has shown that dermatological ADs can be managed without discontinuing ICI therapy. Patients with ADs respond as well or better to ICIs and can be included as candidates in clinical trials. Frequently taken during ICI therapy, steroids impair immunotherapy efficacy in certain an

APA, Harvard, Vancouver, ISO, and other styles

5

Salloum, Antoine, Maya Habre, Joanna Abi Chebl, et al. "Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review." Immunotherapy 14, no. 6 (2022): 489–503. http://dx.doi.org/10.2217/imt-2021-0244.

Full text

Abstract:

Aim: This paper presents the reported dermatological adverse events (AEs) associated with approved combinations of immunotherapy with drugs of the same class, or in combination with targeted therapy or chemotherapy. Materials & methods: PubMed was used as an electronic database, and a total of 29 articles were reviewed which reported dermatological AEs following combination therapies with nivolumab, ipilimumab, axitinib, pembrolizumab, lenvatinib, avelumab, atezolizumab, carboplatin, etoposide, paclitaxel, bevacizumab, pemetrexed, cisplatin and durvalumab. Results: The dermatological AEs r

APA, Harvard, Vancouver, ISO, and other styles

6

Polonskaia, Aleksandra S., Evgeniya A. Shatokhina, and Larisa S. Kruglova. "Balneotherapy as a promising method for the correction of dermatologic adverse events of cancer therapy." Russian Journal of Physiotherapy, Balneology and Rehabilitation 20, no. 6 (2022): 551–58. http://dx.doi.org/10.17816/rjpbr108026.

Full text

Abstract:

Cancer treatment with chemotherapy, targeted and immunotherapy is associated with a wide spectrum of dermatologic adverse events. Xerosis (dryness) of the skin is the most prevalent skin side effect in oncologic patients, which occurs both during treatment with "classic" chemotherapy drugs and modern cancer drugs, such as targeted therapy and immunotherapy. Despite the high prevalence of this side effect, current approaches to the correction of skin xerosis in cancer patients are very limited. At the same time, in the absence of adequate supportive treatment of xerosis, the formation of

APA, Harvard, Vancouver, ISO, and other styles

7

Mazumder, Anika, Kavita Darji, Kristin Smith, and Mary Guo. "Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors." BMJ Case Reports 15, no. 12 (2022): e253059. http://dx.doi.org/10.1136/bcr-2022-253059.

Full text

Abstract:

Bullous pemphigoid is a rare and severe adverse reaction to immune-checkpoint inhibitors that can be life-threatening. Here, we present two cases of bullous pemphigoid secondary to nivolumab and ipilimumab+nivolumab therapy, respectively. Both cases presented months after discontinuation of immunotherapy. Our first case highlights the life-threatening nature of bullous pemphigoid due to its potential to cause laryngeal oedema. Our second case illustrates that cytotoxic T-lymphocyte-associated protein-4 inhibitors can rarely lead to bullous pemphigoid, in addition to programmed cell death-1 (PD

APA, Harvard, Vancouver, ISO, and other styles

8

Pires, Mario Cezar, João Mauricio Martins, F. Montealegre, and Flávia Romero Gatti. "Vitiligo after Diphencyprone for Alopecia Areata." Dermatology Research and Practice 2010 (2010): 1–2. http://dx.doi.org/10.1155/2010/171265.

Full text

Abstract:

The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. Side effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rare adverse effects include an erythema multiforme-like reaction, hyperpigmenttion, hypopigmentation, and vitiligo. We report a 30-year-old, Brazilian male who developed vitiligo lesions following DPCP the

APA, Harvard, Vancouver, ISO, and other styles

9

Kucharczyk, Emilia, Karolina Pawłuszkiewicz, Karol Biliński, Joanna Maj, and Małgorzata Ponikowska. "Intralesional Immunotherapy for Non-Genital Viral Warts: A Review of Current Evidence and Future Perspectives." International Journal of Molecular Sciences 26, no. 12 (2025): 5644. https://doi.org/10.3390/ijms26125644.

Full text

Abstract:

Cutaneous warts caused by human papillomavirus (HPV) are among the most common dermatological conditions, affecting the quality of life of numerous people. Although they are widespread, effective and reliable treatment alternatives are limited, emphasizing the necessity for novel treatment options. Intralesional immunotherapy has emerged as a promising alternative, aiming to stimulate the host immune response to achieve the clearance of both treated and distant lesions. This review explores the immunopathogenesis of cutaneous warts and provides an in-depth analysis of intralesional therapies i

APA, Harvard, Vancouver, ISO, and other styles

10

Rovers, Jessica F. J., and H. Jorn Bovenschen. "Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer." International Journal of Dermatology 59, no. 12 (2020): 1485–90. http://dx.doi.org/10.1111/ijd.15163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Plachouri, Kerasia-Maria, Vaia Florou, Vasileios Georgiou, and Sophia Georgiou. "Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies." Cancers 15, no. 12 (2023): 3126. http://dx.doi.org/10.3390/cancers15123126.

Full text

Abstract:

The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immun

APA, Harvard, Vancouver, ISO, and other styles

12

Williams, Harriet, and Robin Aitchison. "Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis." BMJ Case Reports 12, no. 12 (2019): e232505. http://dx.doi.org/10.1136/bcr-2019-232505.

Full text

Abstract:

Increasing numbers of patients are now offered immunotherapy as part of their cancer treatment. These treatments, while often very effective, have a wide range of adverse effects that are distinct from those of traditional chemotherapy regimens. Thyroid disease, dermatological disease, colitis and pneumonitis are some of the most commonly reported immune side effects. We present a case of life-threatening de novo autoimmune haemolytic anaemia (AIHA) complicated by immune cholangitis induced by pembrolizumab. An 81-year-old woman with metastatic melanoma completed a two-year course of pembroliz

APA, Harvard, Vancouver, ISO, and other styles

13

Santiago Benitez, Mary Jose, Omar López Navarro, Luis Felipe Arias Ruiz, et al. "Stevens-Johnson Syndrome secondary to nivolumab in a patient with mixed cell variety classical Hodgkin Lymphoma." Hematology & Transfusion International Journal 12, no. 4 (2024): 86–90. https://doi.org/10.15406/htij.2024.12.00339.

Full text

Abstract:

The immune checkpoint inhibitors (ICIs) nivolumab and pembrolizumab are some of the principal treatment options for relapsed or refractory classic Hodgkin lymphoma. However, immunotherapy has been related to dermatological adverse events (DAEs) and could lead to discontinuation of cancer treatment in severe cases. DAEs encompass entities such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), SJS/TEN-like reactions, drug reaction with eosinophilia and systemic symptoms (DRESS). We reported a case of a 46-year-old- female with classic mixed cellularity Hodgkin lymphoma, Lugano

APA, Harvard, Vancouver, ISO, and other styles

14

Kulkarni, Maansi, Sean Igelman, Julian Trevino, and Clayton Conner. "Linear Depigmented Macules and Patches in an Elderly Man." SKIN The Journal of Cutaneous Medicine 7, no. 2 (2023): 719–22. http://dx.doi.org/10.25251/skin.7.2.11.

Full text

Abstract:

The development of immune checkpoint inhibitors such as programmed cell-death receptor 1 (PD-1) antagonists has rapidly advanced chemotherapy within the last several decades. PD-1 targeted immunotherapy drugs like pembrolizumab, ipilimumab, nivolumab, and durvalumab have known associations with several immune-mediated dermatological reactions. We report a case in which an elderly male experienced segmental vitiligo after use of durvalumab therapy for small cell lung cancer. Distinct from non-segmental vitiligo, segmental vitiligo presents in a unilateral blaschkoid distribution and typically d

APA, Harvard, Vancouver, ISO, and other styles

15

Nazarova, V. V., A. Yu Syryseva, Z. R. Magomedova, N. V. Danilova, Ye A. Shatokhina, and K. V. Orlova. "The Course of Bullous Pemphigoid Against the Background of Therapy with Immune Response Blockers in Metastatic Melanoma." Effective Pharmacotherapy 21, no. 15 (2025): 12–16. https://doi.org/10.33978/2307-3586-2025-21-15-12-16.

Full text

Abstract:

Therapy with immune checkpoint blockers significantly affected the survival rates of patients with metastatic melanoma. However, immunotherapy may be accompanied by the development of various immune-mediated complications. Skin adverse events are the most common (from 30 to 50% in anti-PD-1 therapy and against the background of combination therapy with anti-PD-1 and anti-CTLA-4). The publication describes a clinical case of a patient with metastatic skin melanoma who developed a rare dermatological adverse event - bullous pemphigoid, against the background of anti-PD-1 inhibitor therapy. Despi

APA, Harvard, Vancouver, ISO, and other styles

16

Mineiro dos Santos Garrett, Náthali Felícia, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz dos Reis, and Christiane Inocêncio Vasques. "Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis." PLOS ONE 16, no. 8 (2021): e0255716. http://dx.doi.org/10.1371/journal.pone.0255716.

Full text

Abstract:

Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated. Objective To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy. Materials and methods We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The prot

APA, Harvard, Vancouver, ISO, and other styles

17

Apalla, Zoe, and Vincent Sibaud. "Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy." Supportive Care in Cancer 28, no. 12 (2020): 5597–99. http://dx.doi.org/10.1007/s00520-020-05701-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Felip, Eudald, Juan Jose Garcia, Noelia Rivera, et al. "Immuno-related cutaneous adverse events (IRcutAEs) of anti-PD-1/anti-PD-L1 therapy in patients (p) with advanced non-small cell lung cancer (NSCLC): A single-institution prospective study." Journal of Clinical Oncology 35, no. 15_suppl (2017): e20556-e20556. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20556.

Full text

Abstract:

e20556 Background: Despite the impressive benefits of the immune checkpoint blockade in NSCLC, its use can be hampered by the occurrence of serious adverse events. IRcutAEs are underestimated and poorly described according to data from the clinical trials. We sought to characterize the IRcutAEs and their treatment in p with NSCLC. Methods: Before starting immunotherapy, all NSCLC p were prospectively referred to the Dermatology Department. Periodic monitoring visits were also scheduled for each p, in order to describe the IRcutAEs and their treatments. The study included data from all consecut

APA, Harvard, Vancouver, ISO, and other styles

19

Syryseva, Anastasiya Yu, Evgeniya A. Shatokhina, Aleksandra S. Polonskaia, Larisa S. Kruglova, Ilya A. Pokataev, and Vsevolod N. Galkin. "Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors." Russian Journal of Skin and Venereal Diseases 27, no. 2 (2024): 121–33. http://dx.doi.org/10.17816/dv623303.

Full text

Abstract:

The discovery of a new group of modern anticancer drugs was a breakthrough in the treatment of cancer. Immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death receptor ligand (PD-L1) may improve prognosis for patients with malignant neoplasms with a high level of microsatellite instability. Despite the high effectiveness of these drugs, immune checkpoint inhibitors can lead to dysregulation of immune responses and the occurrence of adverse reactions associated with an increase in the activit

APA, Harvard, Vancouver, ISO, and other styles

20

Rodriguez Melendez, Elina Alexandra, J. Fabian Martinez Herrera, Guillermo Olivares, et al. "Prevalence of immunotherapy-related adverse events due to checkpoint inhibitors: First report in Mexico." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14090-e14090. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14090.

Full text

Abstract:

e14090 Background: Since 2010, immune checkpoint inhibitors (ICI) have been approved for the treatment of several neoplasms. Their immune-mediated toxicity profile, used as monotherapy (nivolumab [N], Ipilimumab [Ip], pembrolizumab [P]) or in combination (Nivolumab/Ipilimumab [N/Ip]) and their management is still being described, recently. Methods: A retrospective review of medical records, included all cancer patients treated, in our institution, with ICI from January 2014 to February 2018. Frequency, type and grade of immune related adverse events (irAE) by neoplasm, individual agent or comb

APA, Harvard, Vancouver, ISO, and other styles

21

Coussirou, Julie, Magali Ravoire, Alma Stancu, and Léa Vazquez. "Anti-Cancer Drug-Induced Lyell’s Syndrome: A Series of Two Patients." Current Oncology 31, no. 11 (2024): 6891–97. http://dx.doi.org/10.3390/curroncol31110509.

Full text

Abstract:

Lyell’s syndrome or Toxic Epidermal Necrolysis (TEN) is a rare and life-threatening dermatological disease. Most commonly, this syndrome is drug-induced, and is a result of an immune-allergic reaction to medications. Anti-cancer drugs were not the most frequent groups of therapeutic agents related to Lyell’s syndrome, but the emergence of new therapeutic classes, particularly targeted therapy and immunotherapy, is changing current data. We present two cases of Lyell’s syndrome induced by anticancer drugs. (1) TEN in a man treated for metastatic urothelial carcinoma with Enfortumab Vedotin. (2)

APA, Harvard, Vancouver, ISO, and other styles

22

Cui, Wenjuan, Su Wang, Junzhu Xu, Xiaowei Shen, and Murong Hu. "Sintilimab-induced photodistributed bullous pemphigoid: A case report." Medicine 104, no. 6 (2025): e41448. https://doi.org/10.1097/md.0000000000041448.

Full text

Abstract:

Rationale: Immune-checkpoint inhibitors have emerged as a frontline treatment for a growing list of malignancies. Immunotherapy-induced bullous pemphigoid (BP) is a rare dermatological immune-related adverse event of immune-checkpoint inhibitor therapy immune-checkpoint inhibitor therapy. We report a case of immunotherapy-associated BP, with lesions presenting in a photodistribution. This case report aims to emphasize the early recognition of rare clinical manifestations induced by immunotherapy to improve patient prognosis. Patient concerns: The patient was a 77-year-old man with a history of

APA, Harvard, Vancouver, ISO, and other styles

23

Wang, Xiaoxiao, Mariano Suppa, Pascal Bruderer, Nicolas Sirtaine, Sandrine Aspeslagh, and Joseph Kerger. "A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder." Case Reports in Oncology 14, no. 2 (2021): 861–67. http://dx.doi.org/10.1159/000514806.

Full text

Abstract:

Immunotherapy has become the standard of care for various cancer types. The widespread use of immune checkpoints inhibitors confronts us with a whole range of novel immune-related adverse events. Skin toxicity is one of the most frequent adverse events. In this article, we report a case of anti-PD-1 induced late bullous pemphigoid (BP) with mucosal erosions and associated with a troublesome neurological disorder of undetermined origin in a patient with metastatic melanoma. Skin biopsy was essential to make the diagnosis and rapid initiation of systemic prednisolone played a role in favorable c

APA, Harvard, Vancouver, ISO, and other styles

24

Chikhalkar, Siddhi B., Savera Gupta, Snehal Umesh Chopade, Sushanti Jadhav, and Vidya Kharkar. "Successful Remission with Combination of Diphenylcyclopropenone and Apremilast in Refractory Extensive Alopecia Areata." International Journal of Trichology 16, no. 1 (2024): 47–49. https://doi.org/10.4103/ijt.ijt_68_22.

Full text

Abstract:

ABSTRACT Extensive alopecia areata including alopecia totalis and alopecia universalis is a therapeutic challenge in majority of the cases due to poor response to therapy, frequent relapses, minimal chances of spontaneous remission, and the associated psychological distress. Topical immunotherapy with diphenylcyclopropenone (DPCP) is one of the established therapeutic modalities for alopecia areata, although with a variable response rate. The use of systemic corticosteroids and other immunosuppressive drugs such as cyclosporine, azathioprine, and methotrexate is limited by their side effects.

APA, Harvard, Vancouver, ISO, and other styles

25

Manco, Luigi, Ilaria Proietti, Giovanni Scribano, et al. "PET Radiomics Signatures and Artificial Intelligence for Decoding Immunotherapy Response in Advanced Cutaneous Squamous Cell Carcinoma: A Retrospective Single-Center Study." Applied Sciences 15, no. 12 (2025): 6453. https://doi.org/10.3390/app15126453.

Full text

Abstract:

The aim of this study was to develop a baseline [18F]FDG PET/CT model to predict immunotherapy response in advanced cutaneous squamous cell carcinoma (cSCC) and noninvasively determine tumor grade, thereby enhancing early patient stratification. We retrospectively analyzed 59 patients with histologically confirmed advanced cSCC submitted to immunotherapy with cemiplimab. All underwent [18F]FDG PET/CT at baseline and after approximately 12 weeks. Clinical response was assessed through PET findings integrated with clinical and dermatological evaluation, and patients were classified as responders

APA, Harvard, Vancouver, ISO, and other styles

26

Dobrovolskaya, A. N., and L. Yu Karpenko. "Aeroallergens detected in dogs with atopic dermatitis in St. Petersburg and the Leningrad region." International Journal of Veterinary Medicine, no. 2 (June 29, 2023): 394–406. http://dx.doi.org/10.52419/issn2072-2419.2023.2.394.

Full text

Abstract:

Atopic dermatitis is a widespread dermatological disease of dogs, which is caused by the production of immunoglobulin E and accompanied by dermatological lesions. One of the ways to treat this disease is allergen-specific immunotherapy. The purpose of the study was to identify the main causative aeroallergens in dogs with atopic dermatitis and to analyze obtained results (both in relation to individual allergens and their groups). The study, which was conducted on the basis of a veterinary clinic in St. Petersburg, involved 72 dogs that were previously diagnosed with atopic dermatitis. Animals

APA, Harvard, Vancouver, ISO, and other styles

27

Lee, Matthew, and Nagashree Seetharamu. "An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab." Case Reports in Dermatological Medicine 2019 (July 7, 2019): 1–5. http://dx.doi.org/10.1155/2019/4065437.

Full text

Abstract:

Introduction. With the advent of immunotherapy, a new subtype of side effects called IRAEs or immune related adverse effects have become more common. They may present in various organ systems as colitis, pneumonitis, hypophysitis, and thyroiditis and commonly as dermatological reactions. Case. This is a case report of a lung cancer patient that was started on Pembrolizumab and developed shortly after what appeared to be clinically at first pustular psoriasis but on biopsy was confirmed to be lichen planus. She was discontinued on the Pembrolizumab and treated with both systemic and topical ste

APA, Harvard, Vancouver, ISO, and other styles

28

Halliwell, RE. "Efficacy of hyposensitization in feline allergic diseases based upon results of in vitro testing for allergen-specific immunoglobulin E." Journal of the American Animal Hospital Association 33, no. 3 (1997): 282–88. http://dx.doi.org/10.5326/15473317-33-3-282.

Full text

Abstract:

A survey was undertaken to evaluate the responses to hyposensitization in cats for which a diagnosis of allergic disease was made by assessment of clinical signs and evaluation of allergen-specific immunoglobulin E (IgE) using the radioallergosorbent test (RAST). Eighty-one cases were available for analysis. In 39 cases, a dietary change resulted in some subjective improvement, which usually was minimal; however, some cases had significant improvement. In 75.3% of cases, an improvement of at least 50% was noted and ascribed to a combination of immunotherapy and dietary change, when implemented

APA, Harvard, Vancouver, ISO, and other styles

29

Radwanski, Noel E., Daniel O. Morris, Raymond C. Boston, Rosario Cerundolo, and Kenneth W. Lee. "Longitudinal evaluation of immunological responses to allergen‐specific immunotherapy in horses with IgE associated dermatological disease, a pilot study." Veterinary Dermatology 30, no. 3 (2019): 255—e78. http://dx.doi.org/10.1111/vde.12732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chakraborty, Rikhia, Katerina Fagan-Solis, Jessica DeVilla, et al. "Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy." Journal of Clinical Oncology 41, no. 16_suppl (2023): 2588. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2588.

Full text

Abstract:

2588 Background: Immunotherapies, including immune checkpoint inhibitors (ICI), have revolutionized the treatment of many cancers, producing significant improvements in survival in patients with many different cancers. However, the intended anti-tumor effects also result in a unique form of autoimmunity, known as immune-related adverse events (irAEs), which have emerged as a limiting factor for many immunotherapies. Cutaneous irAEs (cirAEs), the most frequently occurring ICI–related toxicities, have been associated with improved efficacy and survival but, in their severe forms, require systemi

APA, Harvard, Vancouver, ISO, and other styles

31

Özistanbullu, Deniz, Ronja Weber, Maria Schröder, et al. "Exploring the Thoughts, Needs and Fears of Chemotherapy Patients—An Analysis Based on Google Search Behavior." Healthcare 12, no. 17 (2024): 1689. http://dx.doi.org/10.3390/healthcare12171689.

Full text

Abstract:

Chemotherapy poses both physical and psychological challenges for patients, prompting many to seek answers independently through online resources. This study investigates German Google search behavior regarding chemotherapy-related terms using Google AdWords data from September 2018 to September 2022 to gain insights into patient concerns and needs. A total of 1461 search terms associated with “chemotherapy” were identified, representing 1,749,312 to 28,958,400 search queries. These terms were categorized into four groups based on frequency and analyzed. Queries related to “adjuvant” and “neoa

APA, Harvard, Vancouver, ISO, and other styles

32

Hanea, Teodora-Elena, Dragoș Goada, and Claudia Cristina Burz. "Multiple Endocrine Toxicities in a Metastatic Cutaneous Melanoma Patient Treated with Checkpoint Inhibitors." Journal of Medical and Radiation Oncology 4, no. 7 (2024): 58–62. http://dx.doi.org/10.53011/jmro.2024.01.08.

Full text

Abstract:

Metastatic cutaneous melanomas are typically treated with first-line checkpoint inhibitors, such as the anti-PD-1 antibody nivolumab and the anti-CTLA-4 antibody ipilimumab. Common immune-related adverse events (irAEs) from these therapies include dermatological, gastrointestinal, and endocrine toxicities. We present a case involving a 51-year-old woman with a prior medical history of Basedow's disease and multinodular goiter, who was diagnosed with metastatic cutaneous melanoma in 2019. Post-surgical intervention addressed most metastatic sites, leaving behind an inoperable axillary adenopath

APA, Harvard, Vancouver, ISO, and other styles

33

Orlova, K. V., and L. V. Demidov. "Possibilities of Pyrexia Correction in Patients with BRAF+ Melanoma Receiving Targeted Therapy." Effective Pharmacotherapy 18, no. 17 (2022): 48–54. http://dx.doi.org/10.33978/2307-3586-2022-18-17-48-54.

Full text

Abstract:

The success of modern drug therapy (targeted and immunotherapy) has significantly changed the prognosis of life of patients with melanoma. Modern approaches to therapy can significantly increase the overall survival of patients with metastatic melanoma, as well as reduce the risk of disease progression after surgical treatment in patients with high-risk skin melanoma and increase overall survival, including when used as adjuvant therapy. Targeted therapy (a combination of drugs dabrafenib and trametinib, vemurafenib and cobimetinib, encorafenib and binimetinib) in most cases is characterized b

APA, Harvard, Vancouver, ISO, and other styles

34

Battyáni, Zita, Cecília Zubonyai, Máté Fehér, et al. "Melanoma arising in a Giant congenital melanocytic nevus in early age: a case report and literature review." Bőrgyógyászati és Venerológiai Szemle 99, no. 6 (2023): 479–88. http://dx.doi.org/10.7188/bvsz.2023.99.6.4.

Full text

Abstract:

Authors present a case of a 37- year-old young female patient, who presented to the emergency department with transient dizziness. The performed cranial MRI confirmed the presence of a solitary brain metastasis. PET CT revealed an FDG-avid active lesion in the lung, with slightly enlarged lymph nodes. The brain tumor was surgically removed and histologically it corresponded to malignant melanoma metastasis. According to tumor board decision combined immunotherapy was initiated. Dermatological examination revealed that the patient was being treated for a histologically neuro-mixoid-appearing me

APA, Harvard, Vancouver, ISO, and other styles

35

Vincent, Jean-Louis. "Editorial: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Clinical trials in immunotherapy for sepsis: Why have the results been so disappointing?" Expert Opinion on Investigational Drugs 5, no. 1 (1996): 1–5. http://dx.doi.org/10.1517/13543784.5.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

İLHAN, Gökçe, Banu DOKUZEYLÜL, Abdullah KAYAR, and Erman OR. "Usage areas of nanoparticles in veterinary dermatology." Journal of Istanbul Veterinary Sciences 7, no. 1 (2023): 34–39. http://dx.doi.org/10.30704/http-www-jivs-net.1263320.

Full text

Abstract:

Elements such as gold and silver have been used to treat various diseases since ancient times. These elements, which are used today, have been diversified and sized with many researches. Recently, it is seen that nanoparticles are frequently used in the medical field. Nanoparticles can be 1-1000 nanometers in size and gain biological, physical and chemical functionality due to their nano size. The type and size of these nanoparticles are chosen according to the area in which they will be used. These prepared drugs are used for purposes such as biosensor imaging, transporting drugs to the targe

APA, Harvard, Vancouver, ISO, and other styles

37

DERTLİOĞLU, Selma Bakar. "A reasonable Response to Diphensiprone in Pediatric Alopecia Patient: A Case Report." Journal of Clinical Case Reports and Studies 2, no. 1 (2021): 01–03. http://dx.doi.org/10.31579/2690-8808/058.

Full text

Abstract:

Alopecia areata (AA) is an autoimmune disorder which accounts for the most frequent cause of inflammation based hair loss among dermatological outpatient attendances. It has an unpredictable course and its etiology has not yet been fully elucidated. Many alternatives treatments are available; however, none of them have been curative or preventive so far. Its treatment must be individualized, and aims at suppressing the phase of activity of the disease. Alopecia areata (AA) persistent for a minimum of 6 months and resistant to other treatments and/or severe AA are indications to use diphencypro

APA, Harvard, Vancouver, ISO, and other styles

38

Ndiaye Diop, MT, B. Seck, K. Diop, et al. "Rapidly fatal anaplastic CD30+ primary cutaneous T-cell lymphoma: about a case." Journal Africain des Cas Cliniques et Revues 9, no. 1 (2025): 176–80. https://doi.org/10.70065/2591.jaccrafri.003l011503.

Full text

Abstract:

CD30+ anaplastic primary cutaneous T-cell lymphoma is a type of cutaneous lymphoma rarely described in the literature and has an exceptional disseminated tumor form. This was a 73-year-old man who presented with nodular skin tumors whose size exceeded 5 cm, firm, painless, secondarily ulcerated, becoming ulcerative budding with a necrotic-purulent background and very painful. These lesions were located on the lower limbs, predominant on the right. Extra-dermatological examination found: right satellite tumor macropolyadenopathy, popliteal, inguinal, axillary and cervical. The rest of the physi

APA, Harvard, Vancouver, ISO, and other styles

39

Salvatierra Velasco, L., S. Sequero, J. Rubio Ubeda, and D. Martinez Peñalver. "AB1327 PREVALENCE OF IMMUNORELATED MUSCULOSKELETAL ADVERSE EFFECTS IN PATIENTS WITH LUNG CANCER OR MELANOMA TREATED WITH IMMUNO-CHECKPOINT INHIBITORS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1769.2–1769. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5360.

Full text

Abstract:

Backgroundmmunotherapy in the field of medical oncology, consisting of inhibiting key immune checkpoints, is revolutionising the way patients with these pathologies are treated, being mainly used in skin and lung tumours.These molecules are aimed at controlling T-cell activation by interacting with cytotoxic T-lymphocyte antigen 4 (CTLA-4) protein (Ipilimumab); by acting on the programmed cell death receptor (PD-1) (Pembrolizumad, Nivolumab); or by binding to programmed cell death ligand 1 (PDL-1) such as Atezolizumad or durvalumad.Despite the improvement in survival in the management of cance

APA, Harvard, Vancouver, ISO, and other styles

40

Ionescu, Sinziana, Alin Codrut Nicolescu, Octavia-Luciana Madge, Laurentiu Simion, Marian Marincas, and Mihai Ceausu. "Intra-Abdominal Malignant Melanoma: Challenging Aspects of Epidemiology, Clinical and Paraclinical Diagnosis and Optimal Treatment—A Literature Review." Diagnostics 12, no. 9 (2022): 2054. http://dx.doi.org/10.3390/diagnostics12092054.

Full text

Abstract:

According to European consensus-based interdisciplinary guidelines for melanoma, cutaneous melanoma (CM) is the most deadly form of dermatological malignancy, accounting for 90% of the deaths of skin cancer patients. In addition to cutaneous melanoma, mucosal melanoma occurs in four major anatomical sites, including the upper respiratory tract, the conjunctiva, the anorectal region, and the urogenital area. As this cancer type metastasizes, a classification used in the current medical literature is the distinction between secondary lesions and primary malignant melanoma of the abdominal cavity

APA, Harvard, Vancouver, ISO, and other styles

41

Venkatesh Lakshmi, Sathya narayanan, and Narasimhalu C R V. "Efficacy of intralesional Purified Protein Derivative (PPD) in the treatment of multiple warts." International Journal of Research in Pharmaceutical Sciences 11, no. 4 (2020): 6850–54. http://dx.doi.org/10.26452/ijrps.v11i4.3656.

Full text

Abstract:

Cutaneous warts are a common dermatological condition caused by the human papillomavirus (HPV) strains 1,2,4 and rarely 57. Although it is a benign condition, it causes disfigurement, pain, discomfort, has a tendency to koebnerize, and can be transmitted to others. This makes adequate and timely treatment important. There are several conventional treatments available which include electrosurgery, cryotherapy and topical medications like imiquimod which show variable responses. Our study evaluated the effectiveness and associated side effects of intralesional PPD for the treatment of multiple w

APA, Harvard, Vancouver, ISO, and other styles

42

Nishigaki, Alice, Julian R. Marchesi, and Renato L. Previdelli. "Faecal Microbiota Transplantation as an Adjuvant Treatment for Extraintestinal Disorders: Translating Insights from Human Medicine to Veterinary Practice." Veterinary Sciences 12, no. 6 (2025): 541. https://doi.org/10.3390/vetsci12060541.

Full text

Abstract:

Faecal microbiota transplantation (FMT) has emerged as a transformative therapy in human medicine, particularly for managing recurrent Clostridioides difficile infections and other gastrointestinal (GI) disorders. Beyond the GI tract, FMT has shown potential in addressing extraintestinal conditions in people, including metabolic, immune-mediated, dermatological, neurological, and infectious diseases. Research in people has highlighted its efficacy in decolonising multidrug-resistant organisms in infection, mitigating autoimmune diseases, and improving outcomes in metabolic disorders such as ob

APA, Harvard, Vancouver, ISO, and other styles

43

Cantos, Blanca, Juan Cristobal Sanchez, Beatriz Nuñez García, et al. "Analyzing inmuno-related adverse event: A real-world DATA study." Journal of Clinical Oncology 39, no. 15_suppl (2021): e18751-e18751. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18751.

Full text

Abstract:

e18751 Background: In the last years, Immunotherapy (IT) has emerged as a standard treatment in an increasing number of tumors. This type of treatment has a specific toxicity profile which is clearly different from chemotherapy, known as an Immuno-related Adverse Event (AEir). We know the data from clinical trials, but little about the incidence and impact of this EAir in our clinical practice. Methods: A retrospective observational study was carried out including all patients from our institution (HUPHM in Madrid) who had received IT, either in monotherapy or in combination between January 20

APA, Harvard, Vancouver, ISO, and other styles

44

Koroleva, I. A., and M. V. Kopp. "The role of cetuximab in treatment of squamous cell carcinoma of the head and neck." Meditsinskiy sovet = Medical Council, no. 21 (December 21, 2024): 30–40. https://doi.org/10.21518/ms2024-513.

Full text

Abstract:

Squamous cell carcinoma of the head and neck (SCCHN) is one of the causes of cancer mortality. The mortality rate of patients within a year from the moment of diagnosis reaches 27% in patients with tumors of the oral cavity and 35.2% in patients with tumors of the pharynx. Despite the visual localization of SCCHN more than 50% of patients at the time of diagnosis are not subject to radical surgical treatment. More than half of the patients develop relapses of SCCHN within 3 years after the end of radical treatment. Most patients with SCCHN receive antitumor drug therapy either when an unresect

APA, Harvard, Vancouver, ISO, and other styles

45

Villa-Crespo, Lorena, Sebastian Podlipnik, Natalia Anglada, et al. "Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival." Cancers 14, no. 5 (2022): 1237. http://dx.doi.org/10.3390/cancers14051237.

Full text

Abstract:

Immune-related adverse events (irAEs) are frequent and could be associated with improved response to immune checkpoint inhibitors (ICIs). A prospective cohort of advanced melanoma patients receiving ICI as first-line therapy was retrospectively reviewed (January 2011–February 2019). A total of 116 of 153 patients presented with at least one irAE (75.8%). The most frequent irAEs were dermatological (derm irAEs, 50%), asthenia (38%), and gastrointestinal (29%). Most irAEs appeared within the first 90 days, while 11.2% appeared after discontinuation of the therapy. Mild grade 1–2 derm irAEs tende

APA, Harvard, Vancouver, ISO, and other styles

46

Afrăsânie, Vlad-Adrian, Teodora Alexa-Stratulat, Bogdan Gafton, et al. "Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors." Cancers 15, no. 4 (2023): 1265. http://dx.doi.org/10.3390/cancers15041265.

Full text

Abstract:

We performed a retrospective study on 51 metastatic melanoma patients treated with Nivolumab in first line, at the Regional Institute of Oncology (RIO) Iasi, Romania between April 2017 and December 2019. We studied the efficacy and safety of anti-PD-1 immune checkpoint inhibitor therapy on a treatment-naive population. After a median follow-up of 36 months, the median progression free survival (PFS) was 26 months (95% CI, 15–36) and the median overall survival (OS) was 31 months (95% CI, 20.1–41.8). At 12 months after the initiation of immunotherapy, the percentage of patients alive was 70%, a

APA, Harvard, Vancouver, ISO, and other styles

47

Yidagur Gangadharaiah Lokesh, Kiran, and Sourav Kumar Mishra. "Efficacy of low-dose nivolumab in advanced cancers: A retrospective analysis from medical oncology clinic in Eastern India." Journal of Clinical Oncology 43, no. 16_suppl (2025): 2598. https://doi.org/10.1200/jco.2025.43.16_suppl.2598.

Full text

Abstract:

2598 Background: Immunotherapy with PD-1/PDL1 blocking monoclonal antibodies has improved survival across several malignancies at different stages of these malignancies. But in Low- & middle-income countries, only 1-3% of cancer patients can access the standard dose of Immunotherapy. In this study, we aim to assess the response to low dose (LD) of Immunotherapy (nivolumab) across a broad range of malignancies. Methods: The study is a retrospective descriptive study. A total of 104 patients with advanced cancers were included in the study. Patients received a lower dose of Nivolumab (20/40

APA, Harvard, Vancouver, ISO, and other styles

48

Elshayeb, Mohamed, Mohamed Farres, Nermine Melek, et al. "Low frequency of CD4+CD25highFOXP3+ T regulatory cells in Egyptian patients with chronic spontaneous urticaria." Egyptian journal of Immunology 28, no. 3 (2021): 176–84. http://dx.doi.org/10.55133/eji.280118.

Full text

Abstract:

hronic urticaria is a prevalent disabling dermatological disease. About 90%, are considered idiopathic and referred to as chronic spontaneous urticaria (CSU), and nearly half of them are likely to have autoimmune mechanisms. Regulatory T cells play a substantial role to prevent autoimmune diseases. Subsets of Tregs expressing the CD4+CD25high and forkhead-box-P3 (FOXP3) transcription factor, crucial for their development and function, are best characterized in maintenance of self-tolerance. The objective of this study was the analysis of peripheral CD4+CD25highFOXP3+(T regs) frequency in chron

APA, Harvard, Vancouver, ISO, and other styles

49

Anukrishna VP, Athulya Subhash, Arun Philip, Pavithran K, and Remya Reghu. "Nivolumab induced cutaneous reactions in a patient with lung cancer– A case study." International Journal of Research in Pharmaceutical Sciences 11, no. 4 (2020): 7376–79. http://dx.doi.org/10.26452/ijrps.v11i4.3920.

Full text

Abstract:

Nivolumab, a PDL1 antagonist is an immunotherapeutic agent that is effectively used for the second-line treatment of advanced or metastatic lung carcinoma. Although Nivolumab improved the overall survival of patients with non-small cell lung cancers in the setting, it is known to result in adverse events called immune-related adverse events (irAEs) like colitis, pneumonitis, skin disorders, and myasthenia gravis. The majority of cutaneous reactions associated with Nivolumab therapy are Grade 1or Grade 2 but Grade 3 skin reactions are very rare. The grade 3 skin reactions are macules or papules

APA, Harvard, Vancouver, ISO, and other styles

50

W. Chambers, Patrick. "Long Covid, the Gut, and Autoimmune Skin Diseases: A Novel Therapeutic Approach." Neuroscience and Neurological Surgery 14, no. 1 (2024): 01–10. http://dx.doi.org/10.31579/2578-8868/297.

Full text

Abstract:

The dermatological manifestations of Long Covid (LC) have languished in the shadows of chronic fatigue and brain fog. Yet they are all linked by gut dysbiosis and the cytokine triad of TNF-α, IL-1β, and IL-6. The gut microbiome common not only to LC, psoriasis, AA, and vitiligo but also to neurodegenerative disease has been recently described. This gut microbiome induces an altered tryptophan metabolism linked to autoimmune disease. SARS CoV2, Mycobacteria, and many intestinal parasites protectively upregulate IFN-γ (less Covid in BCG and in subSaharan Africa), triggering the characteristic al

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!